NVS News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

NV

Mkt Cap

$286.21B

Volume

1.60M

Next Earnings

October 27th

Loading chart

NV

NVSNovartis AG

NVS

Pay with—

Available Balance0.00

NV

Mkt Cap

$285.83B

Volume

1.60M

Next Earnings

October 27th

Chart Financials Earnings News About Dividends Insider Filings

Matchpoint Therapeutics Expands Leadership Team with Appointment of John O’Malley, M.D., Ph.D., as Chief Medical OfficerMatchpoint Therapeutics appointed John O'Malley, M.D., Ph.D., as Chief Medical Officer to lead clinical development of its pipeline of first-in-class oral small molecules for autoimmune and inflammatory diseases. The appointment follows the company's recent $150M Series B financing. Dr. O'Malley brings extensive immunology expertise from previous roles at CRISPR Therapeutics and Sanofi.GlobeNewswire Inc. · Oct 14, 2026

Cancer Stocks to Consider as Oncology Innovation AcceleratesThe global oncology market is experiencing rapid growth due to rising cancer incidence, aging populations, and medical advances including immunotherapies, targeted medicines, and personalized vaccines. Major pharmaceutical companies are investing heavily in oncology R&D, with innovations in antibody-drug conjugates, bispecific antibodies, and next-generation immunotherapies. Three companies highlighted for oncology exposure are Pfizer, Merit Medical Systems, and Abbott Laboratories.Zacks Investment Research · Oct 9, 2026

NVS Wins FDA Nod for Label Expansion of Immunology Drug RhapsidoNovartis received FDA approval for Rhapsido (remibrutinib) for symptomatic dermographism (SD), making it the only prescription treatment approved for both CSU and SD, the two most common forms of chronic hives. The approval was supported by phase III RemIND trial data showing 29.3% complete hive resolution at week 12 versus 14% for placebo. The company is also evaluating remibrutinib in multiple sclerosis, hidradenitis suppurativa, and food allergy. However, Novartis faces pipeline setbacks with failed trials for pelacarsen and del-desiran, and generic competition pressuring blockbuster drugs.Zacks Investment Research · Oct 8, 2026

Novartis advances multiple sclerosis innovation with late-breaking remibrutinib and broad portfolio data at MSToronto2026Novartis will present Phase III REMODEL-1/-2 trial results for remibrutinib, an oral BTK inhibitor for relapsing multiple sclerosis, at MSToronto2026. The company will also showcase expanded evidence for Kesimpta (ofatumumab) across multiple studies including pediatric MS, treatment-naive patients, and pregnancy/breastfeeding outcomes. An investor call will follow the remibrutinib data presentation.GlobeNewswire Inc. · Oct 7, 2026

Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen DealNovartis entered into a licensing agreement with Abogen Biosciences to acquire exclusive worldwide rights to ABO2203, an mRNA-encoded T-cell engager for autoimmune diseases. The deal includes a $575 million upfront payment and up to $7.2 billion in milestone payments. This move aims to strengthen Novartis' immunology pipeline following recent clinical setbacks in pelacarsen and del-desiran programs.Zacks Investment Research · Oct 5, 2026

Sironax Named to Fierce Biotech’s “Fierce 15” List of the Most Innovative and Promising Private Biotechs of 2026Sironax, a clinical-stage biotechnology company, has been recognized by Fierce Biotech as one of the 15 most innovative and promising private biotech companies of 2026. The company is advancing clinical-stage programs including SIR2501 (SARM1 inhibitor), SIR4156 (NAMPT activator), and SIR9900 (RIPK1 inhibitor) for neurodegenerative, metabolic, inflammatory, and immunological diseases. Sironax recently acquired a brain delivery platform to address blood-brain barrier challenges.GlobeNewswire Inc. · Oct 5, 2026

Should You Invest in the VanEck Pharmaceutical ETF (PPH)?The VanEck Pharmaceutical ETF (PPH) offers low-cost exposure to the healthcare-pharma sector with a 0.36% expense ratio and $1.01 billion in assets. The fund tracks the MVIS US Listed Pharmaceutical 25 Index and holds major pharmaceutical companies like Eli Lilly, Merck, and Novartis. With a Zacks ETF Rank of 3 (Hold), year-to-date gains of 6.51%, and a medium-risk profile, PPH is presented as a reasonable option for investors seeking diversified pharma exposure, though alternative ETFs like FTXH and IHE are also available.Zacks Investment Research · Oct 5, 2026

Agios' Growth Story Hinges on Mitapivat's Commercial ExpansionAgios Pharmaceuticals' mitapivat-based drugs (Pyrukynd and Aqvesme) generated $44.7 million in Q2 2026 revenue, up 259% year-over-year, driven by early thalassemia adoption. However, the discontinuation of pipeline drug tebapivat and intensifying competition from Novo Nordisk's etavopivat in sickle cell disease have made the company heavily dependent on mitapivat's commercial success.Zacks Investment Research · Oct 2, 2026

Europe Cancer Metabolism Based Therapeutics Market Forecast to 2035 by Modality, Route, Indication, and Therapy Sales | 25.3% CAGR Drives an $8.54 Billion OpportunityEurope's cancer metabolism-based therapeutics market is projected to grow from $1.12 billion in 2026 to $8.54 billion by 2035, representing a 25.3% CAGR. Growth is driven by Europe's high cancer burden, advances in molecular profiling, precision oncology adoption, and regulatory validation. Small molecules and oral administration routes dominate, with breast cancer and non-small cell lung cancer as leading indications. Key players include AstraZeneca, Bayer, Novartis, Roche, and Servier.GlobeNewswire Inc. · Oct 2, 2026

Autoimmune CAR T Safety Events Reshape Rheumatologist Sentiment, but Autologous CAR T Retains Lead, According to Spherix Global InsightsFollowing trial pauses by Novartis and Bristol Myers Squibb due to safety concerns, rheumatologist confidence in autologous CAR T dropped significantly from 7.5 to 5.2 on a 10-point scale. Despite this, autologous CAR T retained its lead among immune reset modalities at 49% preference. Systemic sclerosis emerged as the clearest near-term opportunity, while delivery infrastructure and safety evidence are now critical differentiators for market adoption.GlobeNewswire Inc. · Oct 1, 2026

to start trading

NV

NVSNovartis AG

NVS

Pay with—

Available Balance0.00

Your PositionYou don't own any NVS yet.

Related Tickers

Earnings

Dividends

Last · Mar 11Annual

Amount$4.77

Yield3.17%

Annual$4.77